目的探讨罗格列酮对肥胖初发2型糖尿病血脂及心外膜脂肪厚度的影响。方法将80例肥胖初发2型糖尿病患者随分为两组,探讨罗格列酮对肥胖初发2型糖尿病患者的血脂,心外膜脂肪厚治疗组40例应用罗格列酮(文迪雅)口服,对照组口服磺脲类降糖药如格列吡嗪等,用药一年进行随访观察,检测两组患者治疗前后血脂,心外膜脂肪厚度。结果治疗组与对照组相对比,能明显控制血脂,心外膜脂肪厚度较好的疗效。 Objective To investigate the effects of rosiglitazone on lipid and epicardial fat thickness in type 2 diabetic patients with newly diagnosed obesity. Methods Eighty patients with newly diagnosed obese type 2 diabetes were divided into two groups to evaluate the effects of rosiglitazone on rosiglitazone in 40 patients with obese newly diagnosed type 2 diabetes mellitus, ) Orally, the control group oral sulfonylureas such as glipizide, medication for one year follow-up observation, two groups of patients before and after treatment of blood lipids, epicardial fat thickness. Results The treatment group compared with the control group, can significantly control the lipid, epicardial fat thickness better curative effect.